Completed
PHASE1
INTERVENTIONAL
NCT06345066
A Study of LY3841136 in Overweight and Obese Participants
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC.
Name:
LY3841136
Type:
DRUG
Description:
Administered SC.
Name:
Placebo
Type:
DRUG
Description:
Administered SC.
Primary Outcomes
Measure:
Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
TimeFrame:
Baseline up to 42 weeks
Description:
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Trial Information
NCT ID
NCT06345066
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025